Valuation: Black Diamond Therapeutics, Inc.

Market Cap 108M 96.46M 89.11M 80.75M 151M 10.25B 154M 1.07B 425M 5.37B 405M 397M 16.94B P/E 2026 *
-3.05x
P/E 2027 * -1.97x
Enterprise Value 108M 96.46M 89.11M 80.75M 151M 10.25B 154M 1.07B 425M 5.37B 405M 397M 16.94B EV / Sales 2026 *
17.3x
EV / Sales 2027 * -
Free-Float
99.34%
Yield 2026 *
-
Yield 2027 * -
1 day-9.62%
1 week+9.30%
Current month-0.27%
1 month-0.53%
3 months+6.82%
6 months-36.70%
Current year-22.63%
1 week 1.71
Extreme 1.71
2.14
1 month 1.6
Extreme 1.6
2.14
Current year 1.6
Extreme 1.6
3.97
1 year 1.6
Extreme 1.6
4.94
3 years 1.2
Extreme 1.195
7.66
5 years 1.18
Extreme 1.18
8.71
10 years 1.18
Extreme 1.18
46.25
Manager TitleAgeSince
Chief Executive Officer 62 16/09/2023
Chief Tech/Sci/R&D Officer 51 11/08/2021
Director of Finance/CFO 41 07/10/2024
Director TitleAgeSince
Director/Board Member 61 01/03/2017
Director/Board Member 47 01/12/2019
Director/Board Member 49 01/12/2018
Date Insider Type Main position Quantity % Market Cap. Importance
18/9/26 Free

Director

7,707 0.0134%
18/9/26 Free

Director

6,801 0.0118%
18/9/26
NEA Management Co. LLC
OtherCompany 0 0% -
Change 5-day change 1-year change 3-year change Capi.($)
-9.62%+9.30%-52.16%-8.29% 108M
+2.41%+0.29%+42.02%+71.57% 64.69B
-0.15%+7.50%+11.42%+71.27% 54.78B
+0.57%+4.60%+7.71%+90.93% 53.49B
+0.37%+4.67%+26.68%+49.64% 45.98B
-1.21%+2.32%+21.50%+118.33% 42.94B
-0.37%+5.07%+243.23%+789.58% 40.08B
+0.05%+0.21%+18.26%+58.53% 33.52B
-0.38%+5.68%+38.39%+28.35% 23.67B
+1.19%-4.98%+26.31%-0.76% 23.97B
Average -0.71%+3.10%+38.34%+126.92% 38.32B
Weighted average by Cap. +0.39%+2.73%+46.45%+143.58%

Financials

2026 *2027 *
Net sales 6.25M 5.58M 5.16M 4.67M 8.74M 593M 8.89M 62.05M 24.56M 311M 23.46M 22.96M 980M -
Net income -36.96M -33.01M -30.49M -27.63M -51.7M -3.51B -52.55M -367M -145M -1.84B -139M -136M -5.8B -64.65M -57.73M -53.33M -48.33M -90.42M -6.14B -91.92M -642M -254M -3.22B -243M -237M -10.14B
Net Debt - -
Projected Income Statement - Annual - Black Diamond Therapeutics, Inc.
Logo Black Diamond Therapeutics, Inc.
Black Diamond Therapeutics, Inc. is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The Company’s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system disease. The Company is advancing a Phase 2 NSCLC trial of BDTX-1535, a brain-penetrant fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR-mutant NSCLC and glioblastoma. Its BDTX-4933 pipeline product is out-licensed to Servier. BDTX-4933 is designed to target RAS and RAF alterations in solid tumors. It is exploring partnership opportunities for its FGFR2/3 selective development candidate BDTX-4876.
Employees
21
Date Price Change Volume
23/10/26 US$1.880 -9.62% 927,809
22/10/26 US$2.080 0.00% 790,955
21/10/26 US$2.080 +0.48% 2,355,483
20/10/26 US$2.070 +14.36% 2,113,789
19/10/26 US$1.810 +5.23% 825,582
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Black Diamond Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
1.880USD
Average target price
10.00USD
Spread / Average Target
+431.91%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Black Diamond Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. BDTX Stock